Skip to content

Study · Not a test of the peptide alone · 2020

3 results

Development of Ligand-Drug Conjugates Targeting Melanoma through the Overexpressed Melanocortin 1 Receptor.

Zhou Y, Mowlazadeh Haghighi S, Liu Z, Wang L, Hruby VJ, Cai M

ACS pharmacology & translational science18 Aug 2020Cited by 8 (Europe PMC)

PMID33073191 (opens in a new tab)PMCIDPMC7551717 (opens in a new tab)DOI10.1021/acsptsci.0c00072 (opens in a new tab)PepBankPUB-33073191
Source linkPubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone3

In this study, Melanotan II was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Melanotan II.

  1. 01LabNot a test of Melanotan II aloneIn vitro (cells)Activity measurement

    In vitro, drug-MT-II conjugates maintained strong binding interactions to MC1R.

    In plain wordsIn lab tests, conjugates of cytotoxic drugs and MT-II kept strong binding to the MC1R receptor.

    Peptide
    Melanotan II
    Outcome
    Not applicableMC1R binding of drug-MT-II conjugates
    Study

    n: not reported in source

    A375 melanoma cells
    Outcome group
    Receptor activity and mechanism · Cancer

    Source sentences

    Summary
    The drug-MT-II conjugates maintain strong binding interactions to MC1R and induce selective drug delivery to A375 melanoma cells through its MT-II moiety in vitro.
    1 context sentence
    Summary · context
    To solve the drug resistance issue, we designed and synthesized ligand-drug conjugates that couple cytotoxic drugs, which have a low cancer resistance issue, with the melanocortin 1 receptor (MC1R) agonist melanotan-II (MT-II), which provides specificity to MC1R-overexpressing melanoma.

    In this study, Melanotan II was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Melanotan II.

  2. 02LabNot a test of Melanotan II aloneIn vitro (cells)Activity measurement

    In vitro, drug-MT-II conjugates induced selective drug delivery to A375 melanoma cells through the MT-II moiety.

    In plain wordsIn cells, conjugates of cytotoxic drugs and MT-II delivered the drug selectively to A375 melanoma cells.

    Peptide
    Melanotan II
    Outcome
    Not applicableSelective drug delivery to A375 melanoma cells by MT-II conjugates
    Study

    n: not reported in source

    A375 melanoma cells
    Outcome group
    Tumor growth · Cancer

    Source sentences

    Summary
    induce selective drug delivery to A375 melanoma cells through its MT-II moiety in vitro.
    1 context sentence
    Summary · context
    To solve the drug resistance issue, we designed and synthesized ligand-drug conjugates that couple cytotoxic drugs, which have a low cancer resistance issue, with the melanocortin 1 receptor (MC1R) agonist melanotan-II (MT-II), which provides specificity to MC1R-overexpressing melanoma.

    In this study, Melanotan II was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Melanotan II.

  3. 03LabNot a test of Melanotan II aloneIn vitro (cells)Activity measurement

    Camptothecin-MT-II (compound 1) inhibited A375 melanoma cell growth with an IC50 of 16 nM.

    In plain wordsIn cells, a camptothecin-MT-II conjugate stopped the growth of A375 melanoma cells at a low concentration.

    Peptide
    Melanotan II
    Outcome
    DecreaseA375 melanoma cell growth inhibition by camptothecin-MT-II
    Study

    n: not reported in source

    A375 melanoma cells
    Outcome group
    Tumor growth · Cancer

    Measurements

    IC50
    16 nM
    A375 melanoma cells

    Source sentences

    Summary
    Furthermore, using camptothecin as the cytotoxic drug, camptothecin-MT-II (compound 1) can effectively inhibit A375 melanoma cell growth with an IC50 of 16 nM.
    1 context sentence
    Summary · context
    To solve the drug resistance issue, we designed and synthesized ligand-drug conjugates that couple cytotoxic drugs, which have a low cancer resistance issue, with the melanocortin 1 receptor (MC1R) agonist melanotan-II (MT-II), which provides specificity to MC1R-overexpressing melanoma.

    In this study, Melanotan II was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Melanotan II.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 09:43 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.